Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. PINK /
  3. CSPCY.PINK

CSPC Pharmaceutical Group Limited (CSPCY PINK) stock market data APIs

$2.9 0(0%) as of July 26, 2024
Price chart is built with Anychart

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, North America, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company has a strategic partnership with Pfizer Inc. to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

CSPC Pharmaceutical Group Limited Financial Data Overview

2.9
2.9
-
2.9
2.9
2.5751-3.6326
8 861 M
10.9259
2 952 M
32 380 M
0.0165
0.0487
0.687
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'CSPCY',
Type: 'Common Stock',
Name: 'CSPC Pharmaceutical Group Limited',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00KHSZX68',
ISIN: NULL,
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - General',
HomeCategory: NULL,
IsDelisted: false,
}

CSPC Pharmaceutical Group Limited Fundamental Data is available in our Financial Data APIs

  • Net Revenue 32 380 M
  • EBITDA 8 225 M
  • Earnings Per Share 0.27
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get CSPC Pharmaceutical Group Limited Earnings via APIs

  • Latest Release 2021-09-30
  • EPS/Forecast 0

Get CSPC Pharmaceutical Group Limited End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get CSPC Pharmaceutical Group Limited latest news via APIs

FOCUS-China's drugmakers can't sell mRNA shots but haven't quit yet

By Andrew Silver SHANGHAI/SUZHOU, China, April 19 (Reuters) - China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messen...

UPDATE 1-China's CSPC Pharma partners with Pfizer for oral COVID treatment

(Adds details in paragraph 2, context in paragraphs 3, 4 and background in paragraph 5) June 29 (Reuters) - Chinese drug maker CSPC Pharmaceutical Group said on Thursday it signed a strategic partner...
Do you have any questions?
support@eodhistoricaldata.com